Optimising the M72/AS01E tuberculosis vaccine candidate phase 3 trial based on the phase 2b trial results

Katie D Dale1, Justin T Denholm2

  • 1Victorian Tuberculosis Program, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Level 5, 792 Elizabeth St, Melbourne, Victoria 3000, Australia; Department of Infectious Diseases, University of Melbourne, At the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia.

Vaccine
|February 1, 2025
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos